Genetic Testing for Successive Cancer Treatment

Singh, Desh Nidhi; Daripelli, Sushma; Elamin Bushara, Mohamed Osman; Polevoy, Georgiy Georgievich; Prasanna, Muthu

doi:10.7759/cureus.49889

Cited by 5 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, individuals can be monitored more closely for the early signs of CRC, allowing for earlier intervention and potentially better outcomes. 137 The detection of mutations such as RAS and BRAF genes can significantly contribute to the early detection and management of CRC, demonstrating the transformative potential of the advanced diagnostic tools. This proactive approach to early identification is essential as it enables the implementation of preventive measures and early treatments, potentially altering the disease’s course.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Benmokhtar,

Laraqui,

Hilali

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: This review article aims to investigate the prevalence and spectrum of rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations, and their connection with geographical location, clinicopathological features, and other relevant factors in colorectal cancer (CRC) patients in the Middle East. Methods: A systematic literature review, employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, was conducted to investigate the association between the frequency of relevant mutations and the descriptive clinicopathological characteristics of CRC patients. Multiple electronic databases, including PubMed, Science Direct, Web of Science, Scopus, and Google Scholar, were searched to analyze the relevant literature. Results: A total of 19 eligible studies comprising 2960 patients with CRC were included in this review. A comprehensive analysis of the collected literature data as well as descriptive and methodological insights is provided. Men were predominant in reviewed studies for the region, accounting for 58.6%. Overall, RAS mutation prevalence was 38.1%. Kirsten RAS Viral Oncogene Homolog (KRAS) mutations were the most common, accounting for 37.1% of cases and distributed among different exons, with the G12D mutation being the most frequent in exon 2 (23.2%) followed by G12V (13.7%), G13D (10.1%), G12C (5.1%), G12A (5.04%), and G12S (3.6%). Neuroblastoma RAS Viral Oncogene Homolog (NRAS) mutations were identified in 3.3% of tumor samples, with the most common mutation site located in exons 2, 3, and 4, and codon 61 being the most common location for the region. The total mutation frequency in the BRAF gene was 2.6%, with the V600E mutation being the most common. Conclusion: The distribution patterns of RAS and BRAF mutations among CRC patients exhibit notable variations across diverse ethnic groups. Our study sheds light on this phenomenon by demonstrating a higher prevalence of KRAS mutations in CRC patients from the Middle East, as compared with those from other regions. The identification of these mutations and geographical differences is important for personalized treatment planning and could potentially aid in the development of novel targeted therapies. The distinct distribution patterns of RAS and BRAF mutations among CRC patients across different ethnic groups, as well as the regional variability in mutation prevalence, highlight the need for further research in this area.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This proactive approach to early identification is essential as it enables the implementation of preventive measures and early treatments, potentially altering the disease’s course. 137 …”

Section: Discussionmentioning

confidence: 99%

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Benmokhtar,

Laraqui,

Hilali

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

Role of folate receptor and CD44 in targeting of docetaxel and paclitaxel fabricated conjugates for efficient cancer therapy

Tatode,

Agrawal,

Taksande

et al. 2025

Journal of Medicine, Surgery, and Public Health

View full text Add to dashboard Cite

Examining Factors Influencing Preventative Cancer Genetic Testing Participation: The Role of Online Support, Caregiving, and Gender (Preprint)

Agrawal,

DaSouza,

Mulgund

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Despite its potential to predict and detect early cancer risks, genetic testing remains underutilized by the public. This study, guided by the Health Belief Model, examined key factors influencing an individual’s willingness to undergo genetic testing for cancer, with a particular focus on gender, caregiver status, and participation in online social support groups. OBJECTIVE To identify the key variable that influences Preventative Cancer Genetic Testing Participation METHODS This study uses data collected from the 2020 Health Information National Trends Survey (HINTS 5 Cycle 4) which includes 2,947 respondents representing 199,510,996 U.S. adults aged 18 and older. Multivariable logistic regression and Survey-Weighted Generalized Linear Models (svyglm) were applied to examine the relationship between cancer genetic testing and caregiver status, participation in online support groups, gender, and constructs associated with the Health Belief Model, while controlling for sociodemographic and health-related characteristics. RESULTS Our findings show that women are more likely to undergo cancer genetic testing, with gender moderating the influence of perceived susceptibility (β = 2.54, p < 0.05) and severity (β = 0.94, p < 0.05) on testing decisions. In line with the Health Belief Model, perceived benefits (β = 0.19, p < 0.05) and cues to action (β = 2.86, p < 0.001) increase the likelihood of testing. Results also show that caregivers of cancer patients (β = 1.25, p < 0.05) and those actively participating in online health support groups (β = 0.47, p < 0.05) are also more likely to engage in cancer genetic testing. CONCLUSIONS Cancer remains a significant health challenge in the U.S., with 1.8 million new cases and 606,520 deaths annually. Early detection is vital for treatment success. This study investigates factors influencing the decision to undergo genetic testing for cancer. Targeted campaigns, particularly in online support groups directed at men, can promote early detection and encourage participation in genetic testing. Future research should explore implementing proactive outreach strategies to encourage wider adoption of genetic testing for cancer. CLINICALTRIAL NA

show abstract

Genetic Testing for Successive Cancer Treatment

Cited by 5 publications

References 45 publications

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Role of folate receptor and CD44 in targeting of docetaxel and paclitaxel fabricated conjugates for efficient cancer therapy

Examining Factors Influencing Preventative Cancer Genetic Testing Participation: The Role of Online Support, Caregiving, and Gender (Preprint)

Contact Info

Product

Resources

About